To summarize, these results clearly delineated RPL22L1 restrict sorafenib response by activating ERK, and suggested that ERKi combined with sorafenib may be an effective treatment regimen for HCC patients with high expression of RPL22L1 (Fig. 4H). This evidence concerns the gene RPL22L1 and hepatocellular carcinoma.